Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"Thymoject + fumaric acid + selenase" is an investigational combination therapy that has been studied for the treatment of psoriasis. The regimen combines Thymoject (an intravenous thymus extract), fumaric acid, and Selenase (an intravenous selenium preparation, specifically sodium selenite). The therapeutic rationale is based on the synergistic immunomodulatory effects of its components to address the underlying immunological basis of psoriasis. Fumaric acid esters are known to be an effective treatment for psoriasis. Thymus extracts contain peptides that regulate immune function, and have been explored in various immune-related conditions, including psoriasis. Selenium is an essential trace element with antioxidant properties. The combination was evaluated in a study of 54 patients, where it reportedly demonstrated a faster healing rate compared to treatment with fumaric acid alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thymoject + fumaric acid + selenase.